Annexon, Inc.
News
Annexon (NASDAQ:ANNX) Given Overweight Rating at Cantor Fitzgerald
Ticker Report Cantor Fitzgerald reaffirmed their overweight rating on shares of Annexon (NASDAQ:ANNX - Free Report) in a research report released on Monday, Benzinga reports. Several other equities analysts also...\n more…
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
Globe Newswire Only Program that has Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Preservation of Photoreceptors in the Fovea Region Critical for Visual Acuity...\n more…
Insider Selling: Annexon, Inc. (NASDAQ:ANNX) EVP Sells $31,020.00 in Stock
Ticker Report Annexon, Inc. (NASDAQ:ANNX - Get Free Report) EVP Ted Yednock sold 5,500 shares of the business's stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $5.64...\n more…
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
Globe Newswire BRISBANE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body...\n more…
Annexon, Inc. (NASDAQ:ANNX) EVP Sells $32,725.00 in Stock
Ticker Report Annexon, Inc. (NASDAQ:ANNX - Get Free Report) EVP Ted Yednock sold 5,500 shares of Annexon stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $5.95, for a...\n more…